Safety of perampanel in patients with motor neuron disease
Phase 1
- Conditions
- amyotrophic lateral sclerosis
- Registration Number
- JPRN-UMIN000026221
- Lead Sponsor
- Department of Neurology, Juntendo University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who are expected to show rapid symptomatic progression. 2. Patients with severe complications. 3. Patients with malignancy. 4. Patients with severe psychiatric symptoms. 5. Patients who participated in another cliniccal trial within 12 weeks. 6. Patients who are judged to be ineligible for study entry by the investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Persistency rate of perampanel at week 48
- Secondary Outcome Measures
Name Time Method